BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21950486)

  • 1. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
    Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
    Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.
    Li R; Diamond SL
    Thromb Res; 2014 Feb; 133(2):203-10. PubMed ID: 24365044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
    Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
    Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
    Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of platelet reactivity in clopidogrel-treated subjects.
    Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
    J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
    Michelson AD; Linden MD; Furman MI; Li Y; Barnard MR; Fox ML; Lau WC; McLaughlin TJ; Frelinger AL
    J Thromb Haemost; 2007 Jan; 5(1):75-81. PubMed ID: 17002661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
    Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
    Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
    Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
    J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
    J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.